Second Sight Medical Products, Inc. (EYES): Price and Financial Metrics


Second Sight Medical Products, Inc. (EYES)

Today's Latest Price: $0.82 USD

0.01 (-1.68%)

Updated Nov 23 6:55pm

Add EYES to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

EYES Stock Summary

  • The ratio of debt to operating expenses for Second Sight Medical Products Inc is higher than it is for about only 0.52% of US stocks.
  • With a year-over-year growth in debt of -100%, Second Sight Medical Products Inc's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for Second Sight Medical Products Inc comes in at -89.31%, a number that bests merely 1.41% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Second Sight Medical Products Inc are SEAC, MRIN, LQDT, KOPN, and RIGL.
  • EYES's SEC filings can be seen here. And to visit Second Sight Medical Products Inc's official web site, go to www.secondsight.com.

EYES Stock Price Chart Interactive Chart >

Price chart for EYES

EYES Price/Volume Stats

Current price $0.82 52-week high $7.36
Prev. close $0.84 52-week low $0.69
Day low $0.82 Volume 127,200
Day high $0.86 Avg. volume 449,325
50-day MA $0.84 Dividend yield N/A
200-day MA $1.49 Market Cap 19.07M

Second Sight Medical Products, Inc. (EYES) Company Bio


Second Sight Medical Products develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the United States, Canada, Europe, and Saudi Arabia. The company was founded in 1998 and is based in Sylmar, California.


EYES Latest News Stream


Event/Time News Detail
Loading, please wait...

EYES Latest Social Stream


Loading social stream, please wait...

View Full EYES Social Stream

Latest EYES News From Around the Web

Below are the latest news stories about Second Sight Medical Products Inc that investors may wish to consider to help them evaluate EYES as an investment opportunity.

The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-o...

Benzinga | September 9, 2020

SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of the Following Companies: Second Sight Medical Products, Inc. (NasdaqGS - EYES), A10 Networks, Inc. (NYSE - ATEN), MoSys, Inc. (NasdaqGS - MOSY)

BALA CYNWYD, PA / ACCESSWIRE / June 23, 2020 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims regarding the following companies for possible breaches of fiduciary ...

Yahoo | June 23, 2020

Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know

Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research | June 3, 2020

Second Sight Medical Products (EYES) Upgraded to Buy: Here's What You Should Know

Second Sight Medical Products (EYES) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | June 3, 2020

Second Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock

Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it closed its previously announced underwritten public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share for aggregate gross proceeds of $7,500,000, prior to deducting underwriting discounts, commissions and other offering expenses.

Yahoo | May 5, 2020

Read More 'EYES' Stories Here

EYES Price Returns

1-mo -3.53%
3-mo -4.09%
6-mo -12.44%
1-year -88.35%
3-year -91.60%
5-year -97.88%
YTD -86.19%
2019 -16.63%
2018 -53.40%
2017 -3.05%
2016 -66.55%
2015 -42.59%

Continue Researching EYES

Want to see what other sources are saying about Second Sight Medical Products Inc's financials and stock price? Try the links below:

Second Sight Medical Products Inc (EYES) Stock Price | Nasdaq
Second Sight Medical Products Inc (EYES) Stock Quote, History and News - Yahoo Finance
Second Sight Medical Products Inc (EYES) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.91 seconds.